Predict your next investment

Oncology Analytics company logo
INTERNET | Internet Software & Services / Healthcare
oncologyanalytics.com

See what CB Insights has to offer


Founded Year

2009

Stage

Series C | Alive

Total Raised

$56.5M

Last Raised

$28M | 1 yr ago

Revenue

$0000 

Mosaic Score

+50 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Oncology Analytics

Oncology Analytics is the creator of a web-based clinical decision support system that provides oncologists with information for optimal use of cancer drugs.

Oncology Analytics Headquarter Location

7000 Central Parkway Suite 1750

Atlanta, Georgia, 30328,

United States

888-916-2616

Latest Oncology Analytics News

09:00 ET Oncology Analytics Releases Report on FDA's Q1 2021 Drug and Indications Approvals

Jun 10, 2021

Report shows 75% increase in new drug approvals compared to Q4 2020; Over 35% granted accelerated approval by the FDA News provided by Share this article Share this article ATLANTA, June 10, 2021 /PRNewswire/ --  Oncology Analytics , a leading data analytics and technology-enabled service company purpose-built for oncology, has released its Q1 2021 quarterly report on the FDA's newly approved anti-cancer drugs and indications and noted a significant increase in approvals from the final quarter of 2020. The report includes comprehensive breakdowns of 17 oncology indications approved in January, February, and March of this year and includes the FDA's approval details, dosage, toxicity, warnings, costs, National Comprehensive Cancer Network (NCCN) comments and analysis by Oncology Analytics' team of board-certified oncology pharmacists. "Comparing the FDA's approval activity in Q1 2021 to Q4 2020 highlights a number of interesting themes, including the significant increase in approvals quarter over quarter," said Dr. Laura R. Bobolts, PharmD, BCOP, Senior Vice President, Pharmacy, Oncology Analytics. "Approved cancer indications were up from 14 to 19, a 36 percent increase, and new cancer drug approvals increased from four to seven, a 75 percent increase. Further, six oncology indications were approved under the FDA's Accelerated Approval Program ." The report also noted three new CAR-T cell indications that were approved in Q1 2021. "That is the most FDA approvals for oncology cell-based gene therapy ever in a single quarter," said Dr. Bobolts. "This includes the approval of the drug Abecma, the first-ever CAR-T cell therapy approved for relapsed, refractory multiple myeloma, along with two additional CAR-T cell indications." Other items of note covered in the Oncology Analytics' report include: The number of new FDA indications for both multiple myeloma and non-small cell lung cancer tripled from Q4 2020 to Q1 2021. The FDA continues an approval pace for new immune checkpoint inhibitor indications of one per month with four approvals for this drug class alone approved in first quarter of 2021. A copy of the report is available for download here . Dr. Bobolts will be discussing the report findings and analysis during a webinar on June 30 at 1:00 p.m. ET. Click here  to register. Oncology Analytics, Inc. provides health plans, providers, and patients with a data-driven, utilization management solution that delivers real-world, evidence-based analytics focused exclusively for oncology. Used by physicians to support 6 million health plan members in the US and Puerto Rico, the Oncology Analytics e-Prior Authorization platform covers the full spectrum of therapeutics, across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy, and supportive care. The extensive pathway library is continuously updated with the latest evidence-based protocols, which provides the most current options for value-based treatment paths for every patient case. For more information, please visit  www.oncologyanalytics.com . SOURCE Oncology Analytics, Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Oncology Analytics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oncology Analytics is included in 6 Expert Collections, including Digital Health 150 (2019).

D

Digital Health 150 (2019)

150 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

S

Startups Streamlining Healthcare Administrative Costs

349 items

Companies partnering with healthcare stakeholders to improve operational efficiency across payment, supply chain, data mgmt, and more.

C

Cancer

4,744 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

D

Digital Health 150 (2020)

150 items

The winners of the second annual CB Insights Digital Health 150.

D

Digital Hospital - 2020

98 items

Startups recreating how healthcare is delivered

D

Digital Health

9,985 items

Companies that use or incorporate digital technology into their health and wellness product/service offerings.

Oncology Analytics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oncology Analytics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.